

**Controlled.**

**Conformable.**

**Predictable.**

Listening carefully to our physician partners, our engineers and scientists have applied their spirit of innovation to the complexities of endovascular repair. The result: a new system that offers clinicians greater control for durable outcomes.



## We lead the way in TEVAR innovation.

- The first thoracic stent graft approved in Europe, U.S., and Japan\*
- The first TEVAR device to reach 100,000 devices distributed
- The first device approved for endovascular treatment of aneurysms, transections, and Type B dissections
- The first to feature a new delivery system that offers controlled, staged deployment
- 20 years of TEVAR experience

\* Conformable GORE® TAG® Device

Learn more at [goremedical.com/predictable](http://goremedical.com/predictable)



**W. L. GORE & ASSOCIATES, INC.**  
Flagstaff, AZ 86004

+65.67332882 (Asia Pacific)  
00800.6334.4673 (Europe)  
800.437.8181 (United States)  
928.779.2771 (United States)

[goremedical.com](http://goremedical.com)

Products listed may not be available in all markets.

GORE®, ACTIVE CONTROL, TAG®, and designs are trademarks of W. L. Gore & Associates. © 2017 W. L. Gore & Associates, Inc. AW0973-EN1 SEPTEMBER 2017



## Introducing

the GORE® TAG® Conformable  
Thoracic Stent Graft with  
ACTIVE CONTROL System



Even patients with complex anatomical challenges such as acute aortic angles can benefit from the GORE® ACTIVE CONTROL System.

Now, endovascular repair of aneurysms, transections, and Type B dissections can be carried out with greater precision than ever.



## Controlled.

The GORE® ACTIVE CONTROL System is the first to feature a new delivery system that offers controlled, staged deployment.

## Proven results in complex procedures.

The new system builds on the established success of the Conformable GORE® TAG® Device, which has demonstrated strong results in aneurysms, transections, and acute and chronic Type B dissections.

\* Consolidated outcomes following 5 years of follow-up in TAG 08-01, TAG 08-02, and TAG 08-03 clinical studies.

## Conformable.

Patients have individual anatomies with unique challenges. The GORE® ACTIVE CONTROL System enhances the exceptional conformability of the stent graft; facilitating the optimized wall apposition that the Conformable GORE® TAG® Device is renowned for.

Through five-year follow-up*		(N = 217)			
Procedural survival	<b>100%</b>	Spinal cord ischemia	<b>3.7%</b>	Fracture	<b>0%</b>
30-day survival	<b>95.4%</b>	Paraplegia	<b>0.5%</b>	Compression	<b>0%</b>
Freedom from device-related reintervention	<b>93.1%</b>	Aortic rupture associated with treated area	<b>1.8%</b>	Migration	<b>0%</b>

## Predictable.

Built on the established success of the Conformable GORE® TAG® Device that has demonstrated long-term freedom from device-related reintervention (93.1%) and low complication rates (zero migrations, fractures, or compressions).\*

Proximal partially uncovered stents for wall apposition in highly angulated anatomy

Fully supported graft material for low spring-back force

Radial fit for customized oversizing based on patient anatomy

Fully covered distal end for decreased risk of septum perforation in Type B dissection

Single-sheath insertion minimizes vessel trauma and the potential for rupture which can occur with multiple sheath insertions

Sheathless delivery catheter facilitates passage and access through tortuous thoracic anatomy

Controlled deployment with GORE® ACTIVE CONTROL System is designed to optimize accuracy, angulation, and apposition

## Purpose-built to deliver new levels of control, with precise placement and trusted conformability.

